Mediterranean diet with or without aerobic exercise for women with familial Mediterranean fever and fatty liver
Official title: Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Elliptical Aerobic Exercise
Run by Cairo University · NCT07130318 · Data updated 2026-11-12
This trial will test whether adding regular aerobic exercise to a Mediterranean diet helps women with familial Mediterranean fever who have non-alcoholic fatty liver disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 55 Years |
| Sex | Women only |
| Enrollment | 40 (estimated) |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Dokki, Giza Governorate) |
| Status | Recruiting |
| Started | May 8, 2025 |
| Main results expected | January 8, 2026 |
| Study ends | January 8, 2026 |
| Registry record updated | August 19, 2025 |
| Trial ID | NCT07130318 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Obese women diagnosed with familial Mediterranean fever who have non-alcoholic fatty liver and are medically cleared to undertake aerobic exercise.
✕Probably not a fit
Women without fatty liver, or those with cardiac, respiratory, renal disease, or active cancer (who are excluded or cannot safely exercise), are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Forty obese women with familial Mediterranean fever and non-alcoholic fatty liver will be assigned to two groups of 20. Both groups will continue colchicine and follow a Mediterranean diet for six months, while the intervention group also performs elliptical aerobic exercise for 40 minutes three times weekly. Liver fat and related laboratory and clinical measures will be collected at baseline and after six months to compare changes between groups. The study is conducted at the Faculty of Physical Therapy, Cairo University.
Why it matters
Potential benefit: If successful, adding aerobic exercise could reduce liver fat and improve liver-related measures and overall health in affected women.
How similar studies have gone: Mediterranean diet and aerobic exercise have improved non-alcoholic fatty liver in other populations, but applying this combination specifically in women with FMF is novel and not well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * familial Mediterrean fever women * obese women * women who have fatty live (non alcoholic type) Exclusion Criteria: * cardiac patients * respiratory disease * renal disease * cancer
Where it's running
-
faculty of physical therapy Cairo university
Dokki, Giza Governorate, Egypt Recruiting
Study contacts
- Principal investigator: Ali MA Ismail, lecturer — Cairo University
- Study coordinator: Ali MA Ismail, lecturer
- Email: ali.mohamed@pt.cu.edu.eg
- Phone: 01005154209
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Additive Physical Activity for Hypothyroidism in Older Women with Glaucoma and Fatty Liver
We’re testing whether adding a treadmill-based exercise program to standard thyroid treatment helps improve health in older women who have subclinical hypothyroidism, glaucoma, and fatty liver.
-
Canakinumab use in FMF and Still's disease patients across real-world care
This real-world study looks at how people with FMF or Still's disease who were treated with canakinumab fare over at least 6 months.
-
Lowering insulin to reduce liver fat production
This study will try a short course of diazoxide to lower insulin and see if it reduces the liver's creation of new fat in adults with obesity, insulin resistance, and MASLD.
-
Efimosfermin alfa for adults with liver impairment
This trial will test a single dose of efimosfermin alfa in adults with cirrhosis-related hepatic impairment from steatotic liver disease, with and without significant alcohol use, to measure drug levels and safety.
-
Efimosfermin alfa for adults with biopsy-confirmed F2 or F3 MASH
This trial will test whether efimosfermin alfa can resolve steatohepatitis and improve liver-related outcomes in adults with biopsy-confirmed F2 or F3 MASH.
-
Efimosfermin alfa injections for adults with F2–F3 MASH
This study tests whether efimosfermin alfa injections are safe and tolerable for adults (18–75) with known or suspected metabolic dysfunction-associated steatohepatitis (MASH) and F2–F3 fibrosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.